Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Applications
- microbiota for Clinical Studies
- Drug Dolution for Liver Metastases
- Drug Dolution for Gastric Cancer
- Actionable Molecular Diagnostic System for Physicians
- Nuclear Medicine for Therapy
- Nuclear Medicine for Theragnostics
- Liposomes - Hollow Nanospheres for Gene Therapy
- Liposomes - Hollow Nanospheres for Cancer Therapy
- Liposomes - Hollow Nanospheres for Ocular Drug Delivery
- Liposomes - Hollow Nanospheres for Brain Drug Delivery
- Liposomes - Hollow Nanospheres for Vaccines
- Liposomes - Hollow Nanospheres for Immunomodulating Response
- Liposomes - Hollow Nanospheres for Tissue Engineering
- Exosomes - Extracellular Vesicles for Validation and Quality Control
- Exosomes - Extracellular Vesicles for Cancer Treatment
- Exosomes - Extracellular Vesicles for Immunomodulating Response
- Exosomes - Extracellular Vesicles for Molecular Therapy
- Exosomes - Extracellular Vesicles for Brain Drug Delivery
- Exosomes - Extracellular Vesicles for Ocular Drug Delivery
Cancer Therapies Equipment Supplied In Europe
112 equipment items found
Manufactured by:CanVirex AG based inBasel, SWITZERLAND
Oncolytic measles viruses as a multiplexed immune-modulating platform for cancer therapy. Cancer remains a medical and social burden worldwide despite several technological advances in the past decades. Conventional cancer treatments such as surgery, chemo-, or radiotherapy are restricted to local therapy or by ...
Manufactured by:Emosis Diagnostics SAS based inIllkirch-Graffenstaden, FRANCE
Primary aim is in assessing procoagulant states associated with cancer and cancer therapies, to inform physician’s decision making on initiating, pursuing or stopping anticoagulant prophylaxis in cancer patient. ...
Manufactured by:Adaptimmune LLC based inPhiladelphia, PENNSYLVANIA (USA)
Our goal is to revolutionize cancer therapy on a global basis by developing TCR T-cell therapies (called SPEAR T-cells) with the potential to treat a wide range of cancer types and patients. Our TCR T-cell therapies have advantages over other immune therapies and cancer ...
by:T3 Pharmaceuticals AG based inBasel, SWITZERLAND
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where they deliver chosen protein payloads into the ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
EZH2 acts as an epigenetic writer and normally places one or more methyl groups on a histone protein, leading to the suppression of gene expression. Some cancers depend on an abnormal pattern of gene expression and re-direct EZH2 to genes that become abnormally repressed. Cancer cells with these abnormal gene expression programs may be more resistant to ...
Manufactured by:Therawis based inMunich, GERMANY
Personalized medicine aims to identify patients who require treatment and subsequently select the right therapy based on individual factors and tumor characteristics, i.e. personalized medicine targets to identify the right patients for the right therapy. Prognostic biomarkers provide information on the risk of disease recurrence whereby predictive ones will ...
by:Edinburgh Molecular Imaging based inEdinburgh, UNITED KINGDOM
Edinburgh Molecular Imaging has a portfolio of agents designed to improve detection and treatment of Cancer. All Agents progressed to date have been found to be safe, specific, sensitive and ...
Manufactured by:Curasight based inKøbenhavn N, DENMARK
Curasight has developed a novel and innovative Theranostics platform for improved cancer diagnose and treatment. The combination of using targeted radionuclide therapy to treat cancer, and a non-invasive PET imaging for diagnosing and monitoring, is known as Theranostics (Therapy + Diagnostics = Theranostics). Curasight’s ...
by:IBA based inLouvain-La-Neuve, BELGIUM
Proteus®PLUS is a unique proton therapy solution for leading cancer centers striving to meet a large and growing patient base's treatment needs while further advancing your clinical reputation in cancer care. Its cutting-edge features can be configured into a tailored solution to meet your research, clinical, and business objectives. ...
by:Edinburgh Molecular Imaging based inEdinburgh, UNITED KINGDOM
Edinburgh Molecular Imaging has a portfolio of agents designed to improve detection and treatment of Cancer. All Agents progressed to date have been found to be safe, specific, sensitive and ...
Manufactured by:Bioprojet based inParis, FRANCE
Oral follow-up treatment of injectable therapy for malignant hypercalcaemia, Palliative treatment of osteolysis of malignant origin with or without hypercalcaemia, in conjunction with specific cancer treatment, In the event of hypercalcaemia, the treatment must be associated with optimal rehydration. ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
XR-18 is a research effort based on the XR-17 technology platform intended to provide enhanced properties that improve clinical formulations and applications of active pharmaceutical ingredients (APIs) for cancer treatment. This effort has recently generated promising data including: Addition of components to existing XR-17 formulation improving certain properties. Synthesis of novel excipients ...
Manufactured by:AJ Vaccines A/S based inKøbenhavn, DENMARK
VesiCulture (BCG Culture) For the treatment of Bladder ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Recombinant human monoclonal antibody expressed in CHO binding to human ANGPT2. Anti-ANGPT2 Therapeutic Antibody is a monoclonal antibody designed for the treatment of ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Bortezomib (brand name: Velcade) is a treatment for multiple myeloma (a cancer of the plasma cells) and mantle cell lymphoma (a cancer of the lymph ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Apealea (paclitaxel micellar) is a patented solvent-free formulation: it applies paclitaxel – a cornerstone within chemotherapy for many different forms of cancer – through Vivesto’s XR-17 technology platform. Apealea is approved by the European regulatory authority EMA for use in combination with carboplatin for the treatment of adult patients with first relapse of ...
Manufactured by:Affimed GmbH based inHeidelberg, GERMANY
The proprietary ROCK platform enables a tumor-targeted approach that can be tailored across hematological and solid tumors. The ROCK (Redirected Optimized Cell Killing) platform allows for a modular approach to generating customizable ICE (innate cell engager) molecules. High-affinity ICE (innate cell engager) molecules, which are created using the ROCK platform, are capable of bivalent NK-cell ...
Manufactured by:Ernst Kratz GmbH based inBerlin, GERMANY
Especially in medical technology innovation is a warranty for future success. Acufirm is your reliable partner by implementing your ideas and special requests with precision and technical know how. Canulas, wires and tube sections for medical devices made from stainless steel or titanium which are used for cancer treatment, CT or endoscopy e.g. can be produced upon request in all variations. In ...
Manufactured by:EnteroBiotix Ltd based inGlasgow, UNITED KINGDOM
Both inside and out, the human body harbours ecosystems of micro-organisms, including bacteria, viruses, fungi and archaea. These microorganisms, their genomic potential and their collective repertoire of activity are known as ‘the ...
Manufactured by:The Menarini Group based inFlorence, ITALY
Elacestrant is a selective estrogen receptor degrader (SERD) evaluated for potential use as a once daily oral treatment in patients with estrogen receptor positive (ER+)/HER2- advanced or metastatic breast cancer. Studies completed to date, including the positive results from the EMERALD phase 3 trial, indicate that the compound has the potential for use as a single agent or in ...